GT Biopharma Inc

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. Its pipeline includes GTB-3650, in Phase 1 trials targeting CD33 on myeloid leukemias and an agonistic camelid; GTB-5550, in a Phase 1 dose-escalation basket trial targeting B7-H3 on advanced solid tumors; and GTB-7550, a preclinical candidate for lupus and other autoimmune disorders. Formerly known as OXIS International, Inc., the company changed its name to GT Biopharma, Inc. in July 2017. Incorporated in 1965, it is based in San Francisco, California.